Relief Therapeutics Unveils Promising Study Results for RLF-OD032

Relief Therapeutics has published new study findings for RLF-OD032, marking an important development in the treatment of phenylketonuria (PKU). The research suggests that RLF-OD032 achieves better absorption when taken in a fasted state compared to the current reference product, KUVAN®. This advancement could lead to more flexible dosing options for patients, potentially improving adherence and convenience.

Following these results, Relief Therapeutics has filed provisional patents in the US, aiming to expand its intellectual property coverage. The study, examining the pharmacokinetics of RLF-OD032 under varying conditions, found it reached similar exposure levels to KUVAN® even without water. Unexpectedly, in the fasted state, RLF-OD032 exhibited superior absorption without needing food or water.

This leads to potential changes in administration timing and conditions, possibly enhancing patient compliance. Relief Therapeutics plans to advance RLF-OD032 through clinical development, with the goal of filing for US approval by the third quarter of 2025.